|
1
|
Stewart BW and Wild CP: World cancer
report 2014. Int Agency Res Cancer. 2014.
|
|
2
|
Torre LA, Islami F, Siegel RL, Ward EM and
Jemal A: Global Cancer in Women: Burden and Trends. Cancer
Epidemiol Biomarkers Prev. 26:444–457. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reeder JG and Vogel VG: Breast cancer
prevention. Cancer Treat Res. 141:149–164. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sotiriou C and Pusztai L: Gene-expression
signatures in breast cancer. N Engl J Med. 360:790–800. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman
PA, et al: Trastuzumab plus adjuvant chemotherapy for operable
HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
De Giorgi U, Rosti G, Frassineti L, Kopf
B, Giovannini N, Zumaglini F and Marangolo M: High-dose
chemotherapy for triple negative breast cancer. Ann Oncol.
18:202–203. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Ruijter TC, Veeck J, de Hoon JP, van
Engeland M and Tjan-Heijnen VC: Characteristics of triple-negative
breast cancer. J Cancer Res Clin Oncol. 137:183–192. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Massova I, Kotra LP, Fridman R and
Mobashery S: Matrix metalloproteinases: Structures, evolution, and
diversification. FASEB J. 12:1075–1095. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Golubkov VS and Strongin AY:
Proteolysis-driven oncogenesis. Cell Cycle. 6:147–150. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sternlicht MD and Werb Z: How matrix
metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol.
17:463–516. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Visse R and Nagase H: Matrix
metalloproteinases and tissue inhibitors of metalloproteinases:
Structure, function, and biochemistry. Circ Res. 92:827–839. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brinckerhoff CE, Rutter JL and Benbow U:
Interstitial collagenases as markers of tumor progression. Clin
Cancer Res. 6:4823–4830. 2000.PubMed/NCBI
|
|
13
|
Roy R, Yang J and Moses MA: Matrix
metalloproteinases as novel biomarkers and potential therapeutic
targets in human cancer. J Clin Oncol. 27:5287–5297. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shin DH, Dier U, Melendez JA and Hempel N:
Regulation of MMP-1 expression in response to hypoxia is dependent
on the intracellular redox status of metastatic bladder cancer
cells. Biochim Biophys Acta. 1852:2593–2602. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ozden F, Saygin C, Uzunaslan D, Onal B,
Durak H and Aki H: Expression of MMP-1, MMP-9 and TIMP-2 in
prostate carcinoma and their influence on prognosis and survival. J
Cancer Res Clin Oncol. 139:1373–1382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cai QW, Li J, Li XQ, Wang JQ and Huang Y:
Expression of STAT3, MMP-1 and TIMP-1 in gastric cancer and
correlation with pathological features. Mol Med Rep. 5:1438–1442.
2012.PubMed/NCBI
|
|
17
|
Boström P, Söderström M, Vahlberg T,
Söderström KO, Roberts PJ, Carpén O and Hirsimäki P: MMP-1
expression has an independent prognostic value in breast cancer.
BMC Cancer. 11:3482011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tavassoli FA and Devilee P: Pathology and
genetics of tumours of the breast and female genital organs. Int
Agency Res Cancer. 2003.
|
|
19
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu M, Hu Y, Zhang MF, Luo KJ, Xie XY, Wen
J, Fu JH and Yang H: MMP1 promotes tumor growth and metastasis in
esophageal squamous cell carcinoma. Cancer Lett. 377:97–104. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ala-aho R and Kähäri VM: Collagenases in
cancer. Biochimie. 87:273–286. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schütz A, Röser K, Klitzsch J, Lieder F,
Aberger F, Gruber W, Mueller KM, Pupyshev A, Moriggl R and
Friedrich K: Lung adenocarcinomas and lung cancer cell lines show
association of MMP-1 expression with STAT3 activation. Transl
Oncol. 8:97–105. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou R, Xu L, Ye M, Liao M, Du H and Chen
H: Formononetin inhibits migration and invasion of MDA-MB-231 and
4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through
PI3K/AKT signaling pathways. Horm Metab Res. 46:753–760. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schveigert D, Cicenas S, Bruzas S,
Samalavicius NE, Gudleviciene Z and Didziapetriene J: The value of
MMP-9 for breast and non-small cell lung cancer patients' survival.
Adv Med Sci. 58:73–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gialeli C, Theocharis AD and Karamanos NK:
Roles of matrix metalloproteinases in cancer progression and their
pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cleator S, Heller W and Coombes RC:
Triple-negative breast cancer: Therapeutic options. Lancet Oncol.
8:235–244. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Prati R, Apple SK, He J, Gornbein JA and
Chang HR: Histopathologic characteristics predicting HER-2/neu
amplification in breast cancer. Breast J. 11:433–439. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Köhrmann A, Kammerer U, Kapp M, Dietl J
and Anacker J: Expression of matrix metalloproteinases (MMPs) in
primary human breast cancer and breast cancer cell lines: New
findings and review of the literature. BMC Cancer. 9:1882009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yokoyama M, Ochi K, Ichimura M, Mizushima
T, Shinji T, Koide N, Tsurumi T, Hasuoka H and Harada M: Matrix
metalloproteinase-2 in pancreatic juice for diagnosis of pancreatic
cancer. Pancreas. 24:344–347. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hilska M, Roberts PJ, Collan YU, Laine VJ,
Kössi J, Hirsimäki P, Rahkonen O and Laato M: Prognostic
significance of matrix metalloproteinases-1, −2, −7 and −13 and
tissue inhibitors of metalloproteinases-1, −2, −3 and −4 in
colorectal cancer. Int J Cancer. 121:714–723. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lengyel E, Schmalfeldt B, Konik E, Späthe
K, Härting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D
and Kuhn W: Expression of latent matrix metalloproteinase 9 (MMP-9)
predicts survival in advanced ovarian cancer. Gynecol Oncol.
82:291–298. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Morgia G, Falsaperla M, Malaponte G,
Madonia M, Indelicato M, Travali S and Mazzarino MC: Matrix
metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2,
MMP-9) markers of prostate cancer. Urol Res. 33:44–50. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mannello F: What does matrix
metalloproteinase-1 expression in patients with breast cancer
really tell us? BMC Med. 9:952011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xuan J, Zhang Y, Zhang X and Hu F: Matrix
metalloproteinase-1 expression in breast cancer and cancer-adjacent
tissues by immunohistochemical staining. Biomed Rep. 3:395–397.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cierna Z, Mego M, Janega P, Karaba M,
Minarik G, Benca J, Sedlácková T, Cingelova S, Gronesova P,
Manasova D, et al: Matrix metalloproteinase 1 and circulating tumor
cells in early breast cancer. BMC Cancer. 14:4722014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Przybylowska K, Kluczna A, Zadrozny M,
Krawczyk T, Kulig A, Rykala J, Kolacinska A, Morawiec Z, Drzewoski
J and Blasiak J: Polymorphisms of the promoter regions of matrix
metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast
Cancer Res Treat. 95:65–72. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kousidou OC, Roussidis AE, Theocharis AD
and Karamanos NK: Expression of MMPs and TIMPs genes in human
breast cancer epithelial cells depends on cell culture conditions
and is associated with their invasive potential. Anticancer Res.
24:4025–4030. 2004.PubMed/NCBI
|
|
39
|
Roy R, Louis G, Loughlin KR, Wiederschain
D, Kilroy SM, Lamb CC, Zurakowski D and Moses MA: Tumor-specific
urinary matrix metalloproteinase fingerprinting: Identification of
high molecular weight urinary matrix metalloproteinase species.
Clin Cancer Res. 14:6610–6617. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Koç M, Ediger D, Budak F, Karadağ M, Oral
HB, Uzaslan E, Ege E and Gözü RO: Matrix metalloproteinase-9
(MMP-9) elevated in serum but not in bronchial lavage fluid in
patients with lung cancer. Tumori. 92:149–154. 2006.PubMed/NCBI
|
|
41
|
Liu H, Kato Y, Erzinger SA, Kiriakova GM,
Qian Y, Palmieri D, Steeg PS and Price JE: The role of MMP-1 in
breast cancer growth and metastasis to the brain in a xenograft
model. BMC Cancer. 12:5832012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hu F, Wang C, Guo S, Sun W, Mi D, Gao Y,
Zhang J, Zhu T and Yang S: δEF1 promotes osteolytic metastasis of
MDA-MB-231 breast cancer cells by regulating MMP-1 expression.
Biochim Biophys Acta. 1809:200–210. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wyatt CA, Geoghegan JC and Brinckerhoff
CE: Short hairpin RNA-mediated inhibition of matrix
metalloproteinase-1 in MDA-231 cells: Effects on matrix destruction
and tumor growth. Cancer Res. 65:11101–11108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ben-Porath I, Thomson MW, Carey VJ, Ge R,
Bell GW, Regev A and Weinberg RA: An embryonic stem cell-like gene
expression signature in poorly differentiated aggressive human
tumors. Nat Genet. 40:499–507. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chandriani S, Frengen E, Cowling VH,
Pendergrass SA, Perou CM, Whitfield ML and Cole MD: A core MYC gene
expression signature is prominent in basal-like breast cancer but
only partially overlaps the core serum response. PLoS One.
4:e66932009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xu J, Chen Y and Olopade OI: MYC and
breast cancer. Genes Cancer. 1:629–640. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wolfer A, Wittner BS, Irimia D, Flavin RJ,
Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov
JP, et al: MYC regulation of a ‘poor-prognosis’ metastatic cancer
cell state. Proc Natl Acad Sci USA. 107:3698–3703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Smith PG, Wang F, Wilkinson KN, Savage KJ,
Klein U, Neuberg DS, Bollag G, Shipp MA and Aguiar RC: The
phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent
apoptosis in diffuse large B-cell lymphoma. Blood. 105:308–316.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Boire A, Covic L, Agarwal A, Jacques S,
Sherifi S and Kuliopulos A: PAR1 is a matrix metalloprotease-1
receptor that promotes invasion and tumorigenesis of breast cancer
cells. Cell. 120:303–313. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Juncker-Jensen A, Deryugina EI, Rimann I,
Zajac E, Kupriyanova TA, Engelholm LH and Quigley JP: Tumor MMP-1
activates endothelial PAR1 to facilitate vascular intravasation and
metastatic dissemination. Cancer Res. 73:4196–4211. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gupta AK, Cerniglia GJ, Mick R, Ahmed MS,
Bakanauskas VJ, Muschel RJ and McKenna WG: Radiation sensitization
of human cancer cells in vivo by inhibiting the activity of PI3K
using LY294002. Int J Radiat Oncol Biol Phys. 56:846–853. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kallel-Bayoudh I, Hassen HB, Khabir A,
Boujelbene N, Daoud J, Frikha M, Sallemi-Boudawara T, Aifa S and
Rebaï A: Bcl-2 expression and triple negative profile in breast
carcinoma. Med Oncol. 28 Suppl 1:S55–S61. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sun B and Xu M: Matrine inhibits the
migratory and invasive properties of nasopharyngeal carcinoma
cells. Mol Med Rep. 11:4158–4164. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
Implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lin W and Tongyi S: Role of Bax/Bcl-2
family members in green tea polyphenol induced necroptosis of
p53-deficient Hep3B cells. Tumour Biol. 35:8065–8075. 2014.
View Article : Google Scholar : PubMed/NCBI
|
